Is ENTX or EPRX more undervalued in 2026?

CirclFi compares Entera Bio Ltd. (ENTX) and Eupraxia Pharmaceuticals Inc. (EPRX) using 13 institutional-grade valuation models. ENTX has a Quality of Company score of 5.6/10 while EPRX scores 1.9/10.

Which is a better buy — ENTX or EPRX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do ENTX and EPRX valuations compare?

ENTX at $1.22 and EPRX at $7.38 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

ENTX vs EPRX Valuation Comparison 2026 — Intrinsic Value Analysis

ENTX

Biotechnology

Entera Bio Ltd.

Quality

5.6

out of 10

Value Trap

WARN

Price

$1.22

Last close

Models

11/13

Active

EPRX

Biotechnology

Eupraxia Pharmaceuticals Inc.

Quality

1.9

out of 10

Value Trap

SAFE

Price

$7.38

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	ENTX Fair Value	ENTX Upside	EPRX Fair Value	EPRX Upside
Bayesian DCF	Intrinsic	$0.37	-69.7%	$1.95	-73.5%
Earnings Power Value	Intrinsic	$0.16	-85.5%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$1.20	-1.4%	$4.13	-42.5%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for ENTX vs EPRX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ENTX vs EPRX — Which Stock Is More Undervalued?

ENTX scores higher with a 5.6/10 quality rating vs EPRX's 1.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Entera Bio Ltd. (ENTX) and Eupraxia Pharmaceuticals Inc. (EPRX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ENTX currently trades at $1.22 with a QOC of 5.6/10, while EPRX trades at $7.38 with a QOC of 1.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).